CA46 Cells








General information
Description | The CA46 cell line is a human cell line derived from a Burkitt's lymphoma, which is a type of non-Hodgkin's lymphoma. This cell line exhibits characteristics typical of a transformed B lymphocyte lineage and was originally established from the malignant cells of a 39-year-old male. CA46 cells are noteworthy for their study in oncology research, particularly in understanding the Epstein-Barr virus (EBV) negative Burkitt’s lymphoma pathogenesis and the underlying molecular biology of B-cell differentiation and transformation. Scientifically, CA46 cells have been instrumental in the study of gene expression related to B-cell development and malignancy. They are EBV-negative, which allows researchers to investigate tumor characteristics and behaviors without the influence of EBV, a common confounder in many lymphoid malignancies. The cell line also provides a useful tool for examining the efficacy of therapeutic agents and the mechanisms of drug resistance in lymphoma, contributing to the development of targeted therapies in hematologic cancers. In research settings, CA46 cells have been used to assess cytotoxic responses to chemotherapeutic agents and to explore signal transduction pathways involved in B-cell proliferation and apoptosis. Their genomic stability and susceptibility to genetic manipulation further enable their use in molecular biology and genetic studies related to cancer research and therapy development. |
---|---|
Organism | Human |
Tissue | Lymphoblast |
Disease | Burkitt lymphoma |
Synonyms | CA-46, CA 46 |
Characteristics
Gender | Male |
---|---|
Morphology | Lymphoblast |
Growth properties | Suspension |
Identifiers / Biosafety / Citation
Citation | CA46 (Cytion catalog number 305082) |
---|---|
Biosafety level | 1 |
Expression / Mutation
Receptors expressed | Complement |
---|---|
Protein expression | Immunoglobulin(Surface And Secreted) |
Antigen expression | HLA B27(the patient was HLA A2, A11, B17, B27) |
Viruses | EBV negative |
Handling
Culture Medium | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
---|---|
Medium supplements | Supplement the medium with 20% heat-inactivated FBS |
Subculturing | Gently homogenize the cell suspension in the flask by pipetting up and down, then take a representative sample to determine the cell density per ml. Dilute the suspension to achieve a cell concentration of 1 x 10^5 cells/ml with fresh culture medium, and aliquot the adjusted suspension into new flasks for further cultivation. |
Split ratio | 1:2 to 1:4 |
Fluid renewal | 2 to 3 times per week |
Freeze medium | As a cryopreservation medium, use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
Handling of cryopreserved cultures |
|
Quality control / Genetic profile / HLA
Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
---|